BGLAP and Parkinson disease: Reduced OCN concentrations in cerebrospinal fluid have been documented in various neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) (Hou et al., 2021; Liu et al., 2023).